Biotech | March 12, 2024
USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
It is the first autotaxin inhibitor to be investigated in cancer patients
It is the first autotaxin inhibitor to be investigated in cancer patients
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Subscribe To Our Newsletter & Stay Updated
